Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Efficacy of Alefacept Treatment in Chronic Plaque Psoriasis
Alefacept is a human LFA-3/IgG1 fusion protein incorporating the external domain of LFA-3, which is expressed on the surface of APCs.4 Alefacept acts by blocking the interaction between LFA-3 and CD2 on the surface of T cells, thereby interfering with the costimulatory step of T-cell activation.
Related Videos
Related Content
